CARM1 and neoplasm: The recent study showing that CARM1 inhibition is a vulnerability for CREBBP/EP300 mutations carrying lymphomas35, prompted us to investigate if other tumor types that are driven by CARM1 substrates may also be responsive to CARM1 inhibitors.